Skip to content
Peptide research

Noopept

Also known as GVS-111 · Omberacetam
Category
Brain & Cognition
Administration routes
Oral
Regulatory status
Not FDA-approved

Noopept is a synthetic dipeptide sold as a nootropic for memory and focus, active at doses roughly 1000 times lower than piracetam. Evidence for cognitive benefit is moderate, but neuroprotection, BDNF upregulation, and mood effects rest mainly on animal and mechanism studies, not confirmed human trials. Safety data beyond about 56 days does not exist. It is not an FDA-approved drug and is sold mainly as an unregulated research-grade or supplement product.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Noopept (N-phenylacetyl-L-prolylglycine ethyl ester, also known as GVS-111) is a synthetic dipeptide derivative rather than a traditional peptide, developed at the Zakusov Institute of Pharmacology in Moscow, Russia, by T.A. Gudasheva. It contains a Pro-Gly dipeptide core with chemical modifications for oral bioavailability and is commonly discussed in peptide therapy contexts as a peptidomimetic nootropic. Structurally derived from the racetam family of nootropics (particularly piracetam), noopept is technically a peptide-based prodrug that achieves its effects at doses roughly 1,000 times lower than piracetam. It is marketed as a nonprescription medicine in Russia for cognitive disorders and is one of the most widely studied nootropic peptides.

Noopept has a very short half-life (~5-10 minutes in rodents) and crosses the blood-brain barrier. Its primary active metabolite, cycloprolylglycine (cPG), persists in the brain for hours and is believed to mediate the longer-term nootropic effects. The same metabolite occurs naturally as a metabolite of IGF-1 and has been independently studied for neuroprotective properties. Noopept's proposed mechanisms of action include enhancement of cholinergic neurotransmission, upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), protection against glutamate excitotoxicity, and modulation of AMPA receptor function.

Preclinical research has demonstrated noopept's neuroprotective effects in Alzheimer's disease models (amyloid-beta toxicity), chronic brain ischemia, and oxidative stress paradigms. One open-label clinical study in patients with mild cognitive disorders showed improvements in cognition comparable to piracetam at much lower doses. The clinical evidence base is limited and most research comes from Russian laboratories; noopept has nonetheless gained international attention in the nootropic community as a potent, low-dose cognitive enhancer with a favorable safety profile.

How it works in the body

A synthetic dipeptide derivative that is rapidly metabolized to cyclo-prolylglycine, which modulates AMPA and NMDA glutamate receptors to enhance long-term potentiation (memory formation). It also increases BDNF and NGF expression in the hippocampus and cortex, promoting neuroplasticity. Active at doses ~1000x lower than piracetam.

Research overview

Noopept has been studied primarily by Russian research groups, with approximately 100-150 PubMed-indexed publications. The Alzheimer's Drug Discovery Foundation (ADDF) Cognitive Vitality report provides a balanced assessment: 'Although noopept is a purported cognitive-enhancing supplement, little clinical evidence supports its use.' Preclinically, noopept has shown neuroprotective effects in several models. In AD models, noopept prevented amyloid-beta induced cell death in PC12 cells and improved fear memory in rats with Meynert basal nuclei AB injections (Ostrovskaya et al., 2008). In an olfactory bulbectomy model, 21 days of noopept treatment improved memory (Ostrovskaya et al., 2007). For cholinergic enhancement, noopept prevents amnesia induced by scopolamine and nicotinic receptor antagonists. For neurotrophins, chronic noopept increased hippocampal NGF and BDNF expression and slightly increased cortical BDNF; acute treatment decreased cortical expression while increasing hippocampal expression. One open-label study (Neznamov & Teleshova, 2009, n=53) in patients with mild cognitive disorders compared noopept (10mg BID) with piracetam (400mg TID): both improved cognition (MMSE increased from 26 to 29 in noopept group), with noopept producing additional anxiolytic and mild antidepressant effects. Limitations include the lack of placebo-controlled trials, reliance on a single research group for most animal data, and use of non-standard animal models.

Who researches Noopept?

Commonly researched by

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(4)

Rated by level of concern

  • Unknown long-term safety (limited data beyond 56 days)

    Moderate

    PMID 19234797; PMID 22500312; PMID 19565831; PMC12193813 (J Xenobiotics 2025)

  • Sleep disturbances (insomnia, vivid dreams)

    Low

    PMID 19008801 (clinical EEG); PMID 22500312 (safety reporting)

  • Increased blood pressure

    Theoretical

    Russian medicinal label: blood-pressure elevation in patients with hypertension, mainly severe hypertension; frequency unknown.

  • Irritability and agitation

    Theoretical

    PMID 18064900; PMID 25739185

Interaction summary(8)

Rated by direction with this peptide

  • Antituberculosis chemotherapy (isoniazid-containing regimens)

    ProtectiveLow

    In 60 patients with newly diagnosed respiratory tuberculosis (Klin Med Mosk 2009), noopept given during the first month of chemotherapy produced functional normalization of the autonomic and antioxidant systems, reduced anxiety manifestations, and decreased the frequency of neurotoxic and cardiotoxic reactions to the antituberculous drugs. This is a single Russian-language study with no published replication and no available randomization/blinding detail - directionally protective, but not a basis for clinical use.

    PMID 19565831

  • Piracetam and other racetam nootropics

    NeutralLow

    Noopept has been studied head-to-head against piracetam in patients and in rats, with broadly comparable effects at roughly 1000-fold lower doses. No study has tested the two together, so using them together has no demonstrated additive benefit and no documented harm.

    PMID 18697252; PMID 19234797; PMID 15934357

  • Benzodiazepines and other GABA-A positive modulators

    CautionTheoretical

    Mechanism shown; interaction untested. Noopept at 1 microM increased the frequency of spike-dependent spontaneous IPSCs in CA1 pyramidal cells by activating inhibitory interneurons (Neurosci Lett 2010), and a separate mouse study measuring 3H-flunitrazepam binding found noopept normalized stress-reduced benzodiazepine-site receptor levels (Eksp Klin Farmakol 2011). The second finding is normalization of a stress-depressed binding level, not direct potentiation of benzodiazepine action. Additive sedation or altered benzodiazepine response is mechanistically conceivable and has never been tested clinically.

    PMID 20382202; PMID 22232906

  • Cholinesterase inhibitors and alpha7-nicotinic agonists (e.g. donepezil, galantamine)

    SynergisticTheoretical

    Mechanism only. Noopept's increase in spontaneous IPSC frequency in rat CA1 pyramidal neurons was almost completely abolished by alpha7 nAChR-selective antagonists, indicating the effect depends on alpha7 receptors on interneurons (Neurosci Lett 2022). Shared-pathway overlap with pro-cholinergic Alzheimer's drugs is plausible, but a shared mechanism can produce occlusion or a ceiling effect just as easily as additive benefit. No combination study exists in animals or humans; direction is an inference, not an observation.

    PMID 36195298

  • Ketamine and general anesthesia

    ProtectiveTheoretical

    In an animal model (Georgian Med News 2019), intranasal noopept given after ketamine anesthesia significantly decreased anxiety and excitability and improved memory recovery and learning, reported as outperforming piracetam and cerebrocurin. A single preclinical report with no human data - not a basis for clinical use.

    PMID 31687967

  • Antidiabetic agents (insulin, incretin-based drugs, sulfonylureas)

    CautionTheoretical

    Rodent evidence for a glucose-lowering signal: noopept normalized GLP-1 and insulin parameters in streptozotocin-diabetic rats without inhibiting DPP-IV (Bull Exp Biol Med 2014); lowered blood glucose and reduced HOMA-IR in diabetic rats, including in an insulin-treated group (2019); and reduced blood glucose alongside neuroprotection in diabetic rats via TRPV1 inhibition (Mol Neurobiol 2021). An additive glucose-lowering effect on top of existing therapy is therefore mechanistically conceivable, but no human metabolic data exist.

    PMID 25065315; PMID 31356906; PMID 34241806; PMID 31776952 (prediabetic mice, DNA-damage endpoint)

  • Stimulants and sympathomimetics (amphetamines, high-dose caffeine)

    CautionTheoretical

    A general-prudence flag only. The underlying irritability/overstimulation profile is rodent-behavioral plus user anecdote (genotype-dependent behavioral activation in mice), and the blood-pressure component is not supported: the only human autonomic dataset found normalization of vegetative function and fewer cardiotoxic events. Additive overstimulation or sleep disruption cannot be excluded given the absence of any dedicated cardiovascular safety study or interaction study in either direction, but nothing positively demonstrates it.

    PMID 18064900; PMID 25739185

  • Alcohol and other CNS depressants

    CautionTheoretical

    Mechanism shown; combination entirely untested. Noopept demonstrably enhances inhibitory synaptic transmission onto hippocampal CA1 pyramidal cells (Neurosci Lett 2010); combined with unstudied pharmacokinetics in the presence of alcohol, additive sedative or cognitive effects are a reasonable concern with no supporting or refuting data.

    PMID 20382202

Known risks(4)

  • Sleep disturbances (insomnia, vivid dreams)

    Mild

    Reported in 5 of 31 patients (16%) in the clinical study. Likely related to noopept's arousal-enhancing and cholinergic effects. Taking doses earlier in the day may mitigate this.

  • Increased blood pressure

    Mild to Moderate

    Reported in 7 of 31 patients (23%) in the clinical study. Blood pressure monitoring is recommended, especially in patients with hypertension.

  • Irritability and agitation

    Mild

    Reported in 3 of 31 patients (10%) in the clinical study. May be dose-dependent. Reducing dose or discontinuing resolves symptoms.

  • Unknown long-term safety (limited data beyond 56 days)

    No controlled studies longer than 56 days are available. Effects of chronic use on brain chemistry, liver function, and other organ systems are not characterized.

Drug interactions(4)

  • Cholinesterase inhibitors (donepezil, rivastigmine, galantamine)

    Noopept enhances cholinergic neurotransmission. Combining with cholinesterase inhibitors could produce excessive cholinergic stimulation including nausea, bradycardia, and GI upset.

  • Other racetams and nootropics (piracetam, aniracetam, phenylpiracetam)

    Additive cognitive-enhancing effects are possible but not well studied. Combining multiple nootropics increases the risk of overstimulation, insomnia, and irritability.

  • Antihypertensive medications

    Noopept may increase blood pressure in some individuals. Monitoring is recommended when combining with blood pressure medications, as dose adjustments may be needed.

  • Sedatives and anxiolytics (benzodiazepines, barbiturates)

    Noopept has anxiolytic properties and may interact with GABAergic sedatives. Effects could be additive or unpredictable. Caution recommended.

Research & benefits

Evidence base

Evidence Level
Limited Clinical / Strong Preclinical
Total Studies
120
Human Studies
53

Clinical evidence for noopept includes several small studies. Among them is an open-label comparison (n=53) in patients with mild cognitive disorders, which showed improvements in cognition, mood, and anxiety with 56 days of treatment at 10mg BID. No placebo-controlled, double-blind trials have been published in English-language journals. Preclinical evidence is more extensive, with neuroprotective effects demonstrated in AD, ischemia, and excitotoxicity models. Almost all published studies originate from Russian laboratories at the Zakusov Institute. Noopept is registered as a nonprescription medicine in Russia.

Researched for(5)

Rated by confidence in the evidence

  • Cognitive enhancement at very low doses (~1000x more potent than piracetam)

    Medium

    Confirmed in animal studies; human evidence limited to small, unblinded Russian clinical trials.

    PMID 18697252 (Neznamov & Teleshova 2008); PMID 19234797 (English translation 2009, no abstract); PMID 19008801 (clinical-EEG 2008); PMID 22500312 (Amelin 2011, stroke); PMC4837574 (2016 mechanistic review)

  • Neuroprotection against amyloid-beta toxicity in Alzheimer's disease models

    Low

    Rodent and neuronal cell studies show protection against beta-amyloid toxicity; no human Alzheimer's trials yet.

    PMID 19145356; PMID 17092975; PMID 16277202; PMID 20184279; PMID 25096780; PMC4837574 (noopept beta-amyloid/AD-model studies)

  • Upregulation of BDNF and NGF in hippocampus and cortex (chronic treatment)

    Low

    Rat data show increased hippocampal NGF and BDNF expression and a smaller cortical BDNF increase after chronic treatment; this study did not assess human biomarkers.

    PMID 19240853; PMC4837574; PMID 21395007 (identifiers unconfirmed)

  • Protection against glutamate excitotoxicity and oxidative stress

    Low

    Shown in cell and animal studies, including diabetic rats; no human trials conducted.

    PMID 33119829 (HIF-1 activation only, not SOD/catalase); PMID 34241806 (TRPV1, oxidative stress, diabetic rats); PMID 11177296; PMID 12711349 (GVS-111 in human cortical neurons, Int J Dev Neurosci 2003); PMC4837574

  • Anxiolytic and mild antidepressant effects alongside cognitive enhancement

    Speculative

    Anxiolytic effect shown in rodent and small human studies; antidepressant effect is not well established.

    PMID 14631499 (learned-helplessness rat model; authors describe an anxiolytic/anti-neurotic effect, not an antidepressant one); PMID 18064900, 15934357, 25739185, PMC4837574 (mechanistic and cognitive data, no antidepressant endpoints); PMID 19565831 (small unblinded trial in TB patients showing anxiety reduction only). No primary source establishes an antidepressant effect for noopept specifically.

Benefits(5)

  • Cognitive enhancement at very low doses (~1000x more potent than piracetam)

    Neznamov & Teleshova 2009 (open-label, n=53, 10mg BID vs piracetam 400mg TID)

  • Neuroprotection against amyloid-beta toxicity in Alzheimer's disease models

    Ostrovskaya et al., Journal of Biomedical Science 2014 (PMC4422191); Ostrovskaya et al. 2008

  • Upregulation of BDNF and NGF in hippocampus and cortex (chronic treatment)

    Ostrovskaya et al., multiple preclinical studies in rats

  • Protection against glutamate excitotoxicity and oxidative stress

    Gudasheva et al., preclinical studies; ADDF Cognitive Vitality review

  • Anxiolytic and mild antidepressant effects alongside cognitive enhancement

    Neznamov & Teleshova 2009 (clinical); Ostrovskaya et al. (preclinical)

Key studies(3)

  1. Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model

    Preclinical (cell model)Differentiated PC12 cells24-72h exposure

    Ostrovskaya RU, Vakhitova YV, Kuzmina USh, et al.

    Journal of Biomedical Science

    2014

    Noopept protected PC12 cells from amyloid-beta(25-35) toxicity in a concentration-dependent manner. The neuroprotective mechanism involved prevention of calcium dysregulation and mitochondrial dysfunction. Effects were observed at nanomolar concentrations.

  2. Neznamov GG, Teleshova ES.

    Neuroscience and Behavioral Physiology

    2009

    Both noopept (10mg BID) and piracetam (400mg TID) improved cognition in patients with mild cognitive disorders (cerebrovascular disease, post-traumatic). Noopept group showed MMSE improvement from 26 to 29. Noopept also produced anxiolytic effects. Side effects included sleep disturbances (5/31), irritability (3/31), and increased blood pressure (7/31).

  3. Alzheimer's Drug Discovery Foundation (ADDF)

    Cognitive Vitality Reports

    2020

    Independent assessment concluding that preclinical evidence is suggestive of neuroprotective benefit but limited by reliance on a single laboratory, non-standard animal models, and noopept's very short half-life. Clinical evidence is insufficient to recommend noopept for cognitive enhancement.

Regulation & availability

Why researchers look at it

Noopept offers cognitive enhancement at remarkably low doses — roughly 1,000 times more potent than piracetam — with additional anxiolytic and neuroprotective properties. As a nonprescription medicine marketed in Russia, it represents one of the few nootropic peptides with real-world regulatory approval.

Estimated cost
$15-40/mo oral tablets/powder (OTC in Russia)
FDA status
Noopept is not FDA-approved and is not eligible for compounding in the US. The Russian medicinal label specifies nonprescription dispensing.
WADA status
Not named in the 2026 WADA list. S0 concerns absence of governmental human therapeutic approval anywhere, rather than FDA approval alone. A compound-specific S6 classification was not verified; athletes should consult their anti-doping authority.
Prescribability
Noopept is not FDA-approved and is not eligible for compounding in the US. Russian omberacetam tablets are dispensed without prescription.
Availability
Noopept is marketed as a nonprescription medicine in Russia. It has no FDA-approved US product, is not sold in US pharmacies, and cannot lawfully be marketed as a dietary supplement or unapproved new drug in the United States. It is not a controlled substance in most countries. Quality and purity from non-pharmaceutical sources may be inconsistent.

International status

  • EU

    Not approved

  • US

    Noopept is not FDA-approved and is not eligible for compounding in the US.

  • Russia

    Registered medicine; manufacturer label specifies nonprescription dispensing.

  • Worldwide

    Legal status varies by country. Russia's manufacturer label specifies nonprescription dispensing; US dietary-supplement marketing is not lawful. Other countries require individual verification.

Regulatory timeline(7)

  1. 1990s
    Noopept (GVS-111) developed at Zakusov Institute of Pharmacology, Moscow
  2. 2000s
    Approved as a medicine in Russia for mild cognitive disorders
  3. 2008
    Preclinical studies demonstrate neuroprotection against amyloid-beta
  4. 2009
    Open-label clinical study comparing noopept with piracetam published
  5. 2014
    PMC publication on noopept neuroprotection in AD cellular model
  6. 2020
    ADDF Cognitive Vitality independent review published
  7. 2020
    FDA flags undeclared noopept in US brain-boosting supplements

Sources & FAQs

Research sources(4)

Frequently asked questions(4)

How does noopept compare to piracetam?

Noopept is approximately 1,000 times more potent than piracetam by weight. While both enhance cognition, noopept also has anxiolytic and neuroprotective properties not prominently seen with piracetam. Noopept is a dipeptide derivative rather than a true racetam and works through partially different mechanisms including BDNF/NGF upregulation.

What is cycloprolylglycine (cPG) and why does it matter?

Cycloprolylglycine (cPG) is noopept's primary active metabolite and persists in the brain for hours after noopept itself is rapidly metabolized (half-life ~5-10 minutes). It also occurs naturally as a metabolite of IGF-1 and has independent neuroprotective properties. It is believed to be responsible for noopept's sustained cognitive effects and is being separately developed for neurological conditions by Neuren Pharmaceuticals.

Is noopept safe for long-term use?

Long-term safety data is limited. The clinical study used 56 days of treatment with mild side effects (sleep disturbances, irritability, blood pressure changes). Without long-term controlled studies, the safety of chronic use beyond 3 months is not established.

Is noopept legal in the United States?

Noopept is not a controlled substance in the US, meaning possession is not illegal. However, it is not FDA-approved and cannot be legally marketed as a dietary supplement or drug. Quality and purity vary significantly between sources.